The tyrosine kinase inhibitor axitinib targets T315I gatekeeper-mutant Philadelphia chromosome-positive leukemias in vitro and in vivo

被引：0
|
作者：
Pemovska, Tea [1 ]
Kontro, Mika [2 ,3 ]
Repasky, Gretchen A. [1 ]
Porkka, Kimmo [2 ,3 ]
Wennerberg, Krister [1 ]
机构：
[1] FIMM, Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, Hematol Res Unit Helsinki, Helsinki, Finland
[3] Univ Helsinki, Helsinki, Finland
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-4763
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4763
引用
收藏
页数：2
相关论文
共 50 条
  • [1] THE TYROSINE KINASE INHIBITOR AXITINIB TARGETS T315I-MUTANT BCR-ABL DRIVEN LEUKEMIAS IN VITRO AND IN VIVO
    Pemovska, T.
    Kontro, M.
    Repasky, G. A.
    Murray, B. W.
    Porkka, K.
    Wennerberg, K.
    HAEMATOLOGICA, 2014, 99 : 342 - 343
  • [2] AXITINIB Targets Gatekeeper-Mutant BCR-ABL1(T315I)-Driven Leukemia in a Distinct And Selective Fashion
    Pemovska, T.
    Johnson, E.
    Kontro, M.
    Repasky, G. A.
    Chen, J.
    Wells, P.
    Cronin, C.
    McTigue, M.
    Kallioniemi, O.
    Porkka, K.
    Murray, B. W.
    Wennerberg, K.
    ANNALS OF HEMATOLOGY, 2015, 94 (SUPPL 1) : 90 - 91
  • [3] Axitinib targets gatekeeper-mutant BCR-ABL1(T315I)-driven leukemia in a distinct and selective fashion
    Pemovska, Tea
    Johnson, Eric
    Kontro, Mika
    Repasky, Gretchen A.
    Chen, Jeffrey
    Wells, Peter
    Cronin, Ciaran N.
    McTigue, Michele
    Kallioniemi, Olli
    Porkka, Kimmo
    Murray, Brion W.
    Wennerberg, Krister
    CANCER RESEARCH, 2015, 75
  • [4] AXITINIB Targets Gatekeeper-Mutant BCR-ABL1(T315I)-Driven Leukemia in a Distinct And Selective Fashion
    Pemovska, T.
    Johnson, E.
    Kontro, M.
    Repasky, G. A.
    Chen, J.
    Wells, P.
    Cronin, C.
    McTigue, M.
    Kallioniemi, O.
    Porkka, K.
    Murray, B. W.
    Wennerberg, K.
    ANNALS OF HEMATOLOGY, 2015, 94 : S90 - S91
  • [5] DYNAMICS OF T315I MUTATION IN PHILADELPHIA POSITIVE PATIENTS ON TYROSINE KINASE INHIBITOR THERAPY
    Horvat, I.
    Antolic, M.
    Sertic, D.
    Zadro, R.
    HAEMATOLOGICA, 2013, 98 : 564 - 564
  • [6] Overall Survival With Ponatinib Versus Allogeneic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemias With the T315I Mutation
    Nicolini, Franck E.
    Basak, Grzegorz W.
    Kim, Dong-Wook
    Olavarria, Eduardo
    Pinilla-Ibarz, Javier
    Apperley, Jane F.
    Hughes, Timothy
    Niederwieser, Dietger
    Mauro, Michael J.
    Chuah, Charles
    Hochhaus, Andreas
    Martinelli, Giovanni
    DerSarkissian, Maral
    Duh, Mei Sheng
    McGarry, Lisa J.
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    CANCER, 2017, 123 (15) : 2875 - 2880
  • [7] T315I Mutation in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: Role for Detection of Mutations
    Joel, Anjana
    Ganesan, Prasanth
    Kannan, Krishnarathnam
    Radhakrishnan, Venkatraman
    Ganesan, Trivadi S.
    Sagar, Tenali Gnana
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2018, 39 (03) : 417 - +
  • [8] Targeted therapy and the T315I mutation in Philadelphia-positive leukemias
    Soverini, Simona
    Iacobucci, Ilaria
    Baccarani, Michele
    Martinelli, Giovanni
    HAEMATOLOGICA, 2007, 92 (04) : 437 - 439
  • [9] In vitro and in vivo inhibition of the T315I mutant BCR/ABL kinase.
    Zhu, Hong
    Hanna, Ehab
    Lohse, Dan
    Stoughton, Silva
    Tam, Betty
    Barrett, Kathy
    Noronha, Glenn
    Dneprovskaia, Elena
    Cao, Jon
    Chow, Chun
    Hwang, Linda
    Mak, Chiching
    McPherson, Andy
    Palanki, Moorthy
    Pathak, Ved P.
    Renick, Joe
    Soil, Richard
    Zeng, Binqi
    Hood, John
    BLOOD, 2006, 108 (11) : 619A - 619A
  • [10] Ponatinib in the leukemia world: why a reevaluation is necessary for Philadelphia chromosome-positive patients with T315I mutation
    Goodrich, Angelina Daisy
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (05) : 513 - 515
12345